

**To:** All Medi-Cal PCPs  
**From:** IEHP – Quality Programs  
**Date:** May 7, 2025  
**Subject:** **2024 Global Quality P4P PCP Program Guide Updates!**

Inland Empire Health Plan (IEHP) has made several updates to the **2024 Global Quality (GQ) P4P PCP Program** in response to Provider feedback and IEHP's considerations on how to best address noted concerns. Updates noted below are effective for the 2024 program year.

### **PAYMENT METHODOLOGY UPDATE:**

- To address concerns that recent cuts to the payment multiplier did not consider options based on Providers' quality performance, IEHP has made the following change: The payment multiplier has been updated and will now be determined based on the Providers' final 2024 Quality Performance Score:

Global Quality P4P Payment Multiplier*				
2024 Quality Score	0 – 0.99	1.00 – 1.99	2.00 – 2.99	≥ 3.00
Payment Multiplier	45.00	47.50	50.00	55.00

*\* The GQ P4P payment multiplier is subject to change based on Network performance and budget limits.*

### **APPENDIX 1 UPDATE:**

- To address concerns that the current Tier benchmarks do not account for health plan performance requirements from DHCS and NCQA, the Tier 1 goal definition has been updated to the following:
  - If baseline is below 25th percentile:** Tier 1 Goal is defined as 10% reduction in non-compliance **AND** must meet the 25th percentile.
  - If baseline is at or above 25th percentile:** Improvement of at least 2% points.

**A webinar will be held to discuss the above changes. Additional details to come.**

### **MEASURE UPDATES:**

- To align with the latest measures updates as published by the National Committee for Quality Assurance (NCQA) for measurement year 2024, the following change has been made to the definition of the Asthma Medication Ratio (AMR) measure:

- IEHP has removed the following three AMR measure Asthma Controller Medications List:

Asthma Controller Medications:	
Description	Prescription
Long-acting beta2- adrenergic agonist (LABA)	Fluticasone furoate-umeclidinium-vilanterol
Long-acting beta2- adrenergic agonist (LABA)	Salmeterol
Long-acting muscarinic antagonists (LAMA)	Tiotropium

Please review the above updates and leverage the **2024 Global Quality P4P PCP Program Guide** to understand your final 2024 performance year scores and incentive earnings.

Thank you for your continued partnership in providing quality healthcare to our Members. As a reminder, all communications sent by IEHP can also be found at: [www.providerservices.iehp.org](http://www.providerservices.iehp.org) > News and Updates > Notices.

If you have any questions, please do not hesitate to contact the IEHP Provider Call Center at 909-890-2054, (866) 223-4347 or email IEHP’s Quality Department at [QualityPrograms@iehp.org](mailto:QualityPrograms@iehp.org).